首页> 外文期刊>The Journal of Urology >Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?
【24h】

Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?

机译:T3a期肾细胞癌是否包括一组均一的患者?

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Renal cell carcinoma invading the perinephric fat is classified as a stage T3a tumor in the 2002 TNM version. Based on long-term followup we examined the prognostic significance of this definition. MATERIALS AND METHODS: We evaluated the outcome in 237 consecutive patients with localized renal cell carcinoma operated on between January 1985 and December 1997. Median followup was 8 years. Disease-free survival was analyzed using univariate and multivariate analyses. Based on this we proposed and tested a new TNM system against the 2002 TNM version. RESULTS: Tumor recurrence was diagnosed in 48 patients (20.2%) at a median of 21.5 months. Diameter based analysis of stage T3a revealed that this was an inhomogeneous group that included patients with small tumors and an excellent prognosis along with patients with large tumors and a poor prognosis. Based on this information we initiated a modified TNM staging system that ignores perinephric fat invasion. In the proposed staging system stage T1a includes tumors 4 cm or less and stage T1b includes tumors more than 4 but 7 cm or less. Stage T2 is divided into T2a-tumors greater than 7 but 10 cm or less and T2b-tumors greater than 10 cm. Stage T3a is reserved for renal vein tumor invasion. The proposed TNM performed better than the 2002 version using the Nagelkerke R(2) test (0.439 vs 0.359), and the Hosmer and Lemeshow test (0.335 vs 0.191). CONCLUSIONS: The current definition of stage T3a renal cell carcinoma embraces an inhomogeneous group of patients with marked differences in prognosis. We believe that tumor invasion into the perinephric fat does not necessarily predict aggressive biological behavior.
机译:目的:在2002年TNM版中,侵犯肾周脂肪的肾细胞癌被分类为T3a期肿瘤。基于长期随访,我们检查了该定义的预后意义。材料与方法:我们评估了1985年1月至1997年12月间连续进行的237例局部性肾细胞癌患者的结局。中位随访时间为8年。使用单变量和多变量分析来分析无病生存期。基于此,我们提出并针对2002 TNM版本测试了新的TNM系统。结果:48例患者(20.2%)被诊断为肿瘤复发,中位数为21.5个月。基于直径的T3a期分析显示,这是一个不均匀的人群,包括肿瘤小,预后良好的患者以及肿瘤大,预后不良的患者。基于此信息,我们启动了一个改进的TNM分期系统,该系统忽略了会阴部脂肪的侵入。在提议的分期系统中,阶段T1a包括4 cm或更小的肿瘤,阶段T1b包括4 cm或更小的肿瘤。 T2期分为大于7到10 cm或更小的T2a肿瘤和大于10 cm的T2b肿瘤。 T3a期保留用于肾静脉肿瘤浸润。使用Nagelkerke R(2)测试(0.439对0.359)以及Hosmer和Lemeshow测试(0.335对0.191),建议的TNM的性能优于2002版。结论:目前对T3a期肾细胞癌的定义包括一组不均匀的患者,其预后差异显着。我们认为,肿瘤浸润到会阴脂肪中并不一定预示着侵略性生物学行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号